Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 368 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06488625RecruitingPhase 2/Phase 3
Nicotinamide for mild to moderate ulcerative colitis
This trial tests whether a special oral form of nicotinamide (a type of vitamin B3) can help control mild to moderate ulcerative colitis. The pill is designed to release the medication in the lower part of your gut, where UC often affects. Participation involves taking the study drug and having regular checkups to see how your symptoms and inflammation respond.
Kiel, Schleswig-HolsteinAges 18–80 - NCT06488924RecruitingPhase 1/Phase 2
Study of JR-446 for Sanfilippo syndrome type B
This trial tests an experimental drug, JR-446, for children with Sanfilippo syndrome type B (MPS IIIB). The goal is to see if it is safe and can help with symptoms.
HiroshimaAges Up to 17 years - NCT06490757RecruitingPhase 2
Testing a pill for large inflamed liver growths
This trial tests a daily pill (baricitinib) to shrink large, inflamed liver growths called inflammatory hepatocellular adenomas. It may be an option for people who have at least one growth larger than 5 cm and who are not using estrogen-containing birth control.
BobignyAges 18–65 - NCT06494111RecruitingPhase 2
Preventing neck swelling after radiation for throat cancer
This study tests two medicines—pravastatin (a statin) and a combination of pentoxifylline and Vitamin E—to see if they can prevent long-term swelling (lymphedema) and scarring in the neck after radiation therapy for throat cancer. Participants receive one of the medicines daily for 2 years, and regular scans help monitor any changes.
Houston, TexasAges 18 years+ - NCT06498089RecruitingPhase 4
Comparing tailored vs. standard treatment for active Takayasu's arteritis.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06514534RecruitingPhase 2
Asciminib for CML with T315I mutation and ponatinib problems
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
BordeauxAges 18–99 - NCT06517004RecruitingPhase 1
Study of JWCAR201 for relapsed or refractory large B-cell lymphoma
This trial tests a new cell therapy called JWCAR201 for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to at least two prior treatments. The goal is to see if this treatment can help when standard options have stopped working.
ShanghaiAges 18 years+ - NCT06541847RecruitingPhase 2
Testing HLX-1502 for NF1 with Plexiform Neurofibromas
This trial tests an experimental drug called HLX-1502 for people with NF1 who have a plexiform neurofibroma (a type of nerve tumor) that is growing or causing problems. It aims to see if the drug is safe and can shrink or stop the tumor from worsening.
Birmingham, AlabamaAges 12 years+ - NCT06542237RecruitingPhase 1/Phase 2
Study of a new male birth control pill for healthy men
This trial tests an experimental birth control pill (YCT-529) taken daily. It aims to see if the drug can safely and effectively prevent pregnancy in healthy men who do not plan to have children in the future.
Grafton, AucklandAges 28–70 - NCT06542991Recruiting
Transcranial magnetic stimulation for Parkinson's disease
This study tests whether repetitive transcranial magnetic stimulation (rTMS) can help people with Parkinson's disease. You will receive rTMS and be evaluated for changes in movement and thinking.
Hefei, AnhuiAges 40 years+ - NCT06553872RecruitingPhase 2
Pirtobrutinib and CAR T-cell therapy for mantle cell lymphoma
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
Stanford, CaliforniaAges 18 years+ - NCT06557161RecruitingPhase 2
Stem cell transplant with TBI or TMLI for adult ALL
This trial tests two different conditioning regimens (total body irradiation or total marrow/lymphoid irradiation) before a stem cell transplant from a matched sibling donor for adults with acute lymphoblastic leukemia (ALL) that is in remission. The goal is to see which regimen works better and has fewer side effects.
Zhengzhou, HenanAges 18–65 - NCT06559345RecruitingPhase 2
Stem cell transplant study for children with ALL in remission
This trial tests a stem cell transplant using a half-matched family donor for children with acute lymphoblastic leukemia (ALL) that is in remission. It compares two different types of radiation conditioning to prepare the body for the new cells, with the goal of improving outcomes.
Zhengzhou, HenanAges 1–17 - NCT06564493RecruitingPhase 2
Radiation conditioning before sibling stem cell transplant for pediatric ALL
This study tests two types of radiation-based conditioning (TBI or TMLI) before a stem cell transplant from a matched sibling donor, in children with ALL that is in remission. The goal is to see which approach works better and is safer.
Zhengzhou, HenanAges 1–17 - NCT06564545RecruitingPhase 2
Radiation-based transplant preparation for adult ALL
This trial studies a new way to prepare adults with ALL for a stem cell transplant from a half-matched family donor. It compares two types of radiation-based conditioning to see which works better and has fewer side effects.
Zhengzhou, HenanAges 18–65 - NCT06577779RecruitingPhase 4
Testing Jornay PM for adult ADHD symptoms into the evening
This study tests if Jornay PM, a long-acting ADHD medication, helps control symptoms, focus, and emotions throughout the day and into the early evening in adults with ADHD. It is an open-label study, meaning everyone knows they are getting the medication, and then they are randomly assigned to different observation groups.
New York, New YorkAges 18–60 - NCT06581562RecruitingPhase 1
Testing rituximab plus AB-101 for autoimmune diseases
This trial tests a new treatment (AB-101) combined with rituximab for people with certain autoimmune diseases like rheumatoid arthritis, pemphigus vulgaris, vasculitis, or lupus. It is for those who have not had success with standard therapies.
Plantation, FloridaAges 18 years+ - NCT04638647RecruitingPhase 4
Continue secukinumab after prior study, without safety issues
This trial lets people who already did a previous secukinumab (an injection for certain inflammatory conditions) study continue treatment afterward. It’s mainly for people who are still getting benefit and can’t otherwise get the approved medication through their local system.
Fullerton, CaliforniaAges 6–100 - NCT07456891RecruitingPhase 3
Long-term access to remibrutinib for skin or allergy patients
This trial provides ongoing access to remibrutinib for people who were previously in a Novartis study and are still benefiting from the drug. It is for those who cannot get the marketed version yet.
SofiaAges 18–100 - NCT05718817Enrolling by invitationPhase 3
Long-term study of XEN1101 for people with epilepsy
This study gives XEN1101 in an open-label way (everyone knows they’re getting the drug) to people who finished earlier epilepsy studies. It aims to see how the treatment continues to work and whether it’s safe over the long term.
Phoenix, ArizonaAges 12 years+ - NCT06614894RecruitingPhase 2/Phase 3
High dose ambroxol for adults with Sanfilippo syndrome
This trial tests a high dose of a medicine called ambroxol in adults with MPS III (Sanfilippo syndrome). It aims to see if the drug is safe and can help symptoms.
Fairfax, VirginiaAges 18–99 - NCT06616766RecruitingPhase 1/Phase 2
Study of a new drug for advanced cancers with HER2 or EGFR changes
This trial tests a new medication (YH42946) for people with advanced solid tumors that have specific genetic changes in HER2 or EGFR. It aims to see if the drug is safe and effective for those who have exhausted other treatments.
Fairfax, VirginiaAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06634849RecruitingPhase 1/Phase 2
Study of a new drug (PTT-4256) for advanced solid tumors
This trial tests a new drug called PTT-4256 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it helps shrink or control the cancer.
Blacktown, New South WalesAges 18 years+
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 368 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.